A detailed history of Acadian Asset Management LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 217,285 shares of LYEL stock, worth $152,099. This represents 0.0% of its overall portfolio holdings.

Number of Shares
217,285
Holding current value
$152,099
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$0.59 - $1.48 $128,198 - $321,581
217,285 New
217,285 $139,000
Q1 2024

May 10, 2024

BUY
$1.71 - $3.07 $133,297 - $239,312
77,952 New
77,952 $173,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $173M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.